Effect of ursodeoxycholic acid on the pharmacokinetics of enalapril and its active metabolite enalaprilat in mice: Implications for transporter-mediated drug-drug interaction.
Abstract
Ursodeoxycholic acid (UDCA) has been reported to alter the expression of hepatic transporters, such as organic anion-transporting polypeptides (OATPs), and multidrug resistance-associated proteins (MRPs). This study investigated the pharmacokinetic interactions between UDCA and enalapril-a substrate of hepatic Oatp1a1 and Mrp2-and its active metabolite enalaprilat, a substrate of Mrp4 and organic anion transporter 3 (Oat3), in mice fed a 1% UDCA-diet for seven days. In UDCA-diet mice, hepatic Oatp1a1 and Oatp1b2 mRNA expression levels were significantly reduced, whereas Mrp4 expression was upregulated. Following an intravenous bolus of enalapril (2 mg/kg), UDCA-diet mice exhibited increased systemic exposure (AUC0-∞) and peak plasma concentration (Cmax) of enalapril, whereas the hepatic distribution and volume of distribution at steady state (Vss) declined. Consequently, the ratio of the area under the plasma concentration-time curve for enalaprilat to that for enalapril (AUCm/AUCp) decreased. Although the total area under the plasma concentration-time curve from time zero to infinity (AUC0-∞) for enalaprilat remained unchanged, Cmax increased. Furthermore, the renal clearance of enalaprilat decreased, potentially due to UDCA-mediated inhibition of renal Oat3. These findings demonstrate that high UDCA exposure alters the disposition of enalapril and enalaprilat by modulating hepatic and renal transporters, supporting the potential for transporter-associated drug interactions under elevated UDCA exposure.